



Sunil K. Ghosh, Grant S. Buchanan, Quincy A. Long, Yonggang Wei, Ziyad F. Al-Rashid,
Heather M. Sklenicka, Richard P. Hsung*

Received 22 June 2007; accepted 26 September 2007
Available online 24 October 2007


[3+3] Annulations of *exo*-cyclic vinylogous amides and urethanes with vinyl iminium salts are described here. We observed an intriguing dichotomy in their reaction pathways. For pyrrolidine- and azepane-based vinylogous amides or urethanes, aza-[3+3] annulation would dominate to give tetrahydroindolizidines, whereas, unexpectedly, for piperidine-based vinylogous amides or urethanes, carbo-[3+3] annulation was the pathway, leading to hexahydroquinolines. The origin for such a contrast is likely associated with a switch in the initial reaction pathway between C-1,2-addition and C-1,4-addition.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Aza-[3+3] annulation; Carbo-[3+3] annulation; Vinylogous amides; Quinolines; Tetrahydroindolizidines

Aza-[3+3] annulation or formal cycloaddition reaction has emerged as a formidable strategy in the synthesis of alkaloids.^{1–5} Specifically, our intermolecular aza-[3+3] annulation⁵ involves a Knoevenagel-type condensation of vinyl iminium ions **1** with vinylogous amides or urethanes **2** followed by a 6 π -electron electrocyclic ring-closure of 1-azatrienes **3**^{6,7} en route to 1,2-dihydropyridines **4** (Scheme 1). This annulation process provides a unique opportunity to develop approaches toward a stereoselective ring-closure of 1-azatrienes, which had represented a real challenge in such pericyclic processes.^{6,8}

Efforts in developing such a torquoselective⁹ reaction have been largely overlooked. An elegant exception would be Tanaka and Katsumura's electrocyclic ring-closure using chiral amines.¹⁰ In our own work, we employed either chiral iminium ions **1** with a preexisting stereogenic center in the




Scheme 1. An aza-[3+3] annulation.

β -substituent,¹¹ or 1-azatrienes **5** containing a chiral N-auxiliary^{12,13} (see the box in [Scheme 1](#)) en route to 1,2-dihydropyridines **4** or 1-azadecalins **6**.

* Corresponding author.

E-mail address: rphsung@pharmacy.wisc.edu (R.P. Hsung).




Scheme 2. An intramolecular aza-[3+3] annulation.

Although by a very different mechanism,¹³ we have exerted much efforts in the last few years in developing both a diastereoselective¹⁴ and an amine salt-catalyzed asymmetric¹⁵ intramolecular aza-[3+3] annulation reaction employing vinylogous amides tethered with α,β -unsaturated iminium salts **7** (Scheme 2). This annulation provides a powerful synthetic strategy to construct nitrogen heterocycles **8** that can lead to a range of prevalent structural motifs among alkaloids.

We have already successfully applied this strategy toward total syntheses of several alkaloids such as (+)-gephyrotoxin,¹⁴ ($\pm$)-tangutorine,¹⁶ (+)/(-)-deplancheine,¹⁷ and (-)-cylindricine C,¹⁸ and most recently, five members of the azaphenalene alkaloid family (see Fig. 1).¹⁹

Despite our understanding of this annulation reaction, we encountered a rather intriguing and unexpected outcome during our efforts in achieving total syntheses of azaphenalene alkaloids. As shown in Scheme 3, we found that intramolecular aza-[3+3] annulations of *exo*-cyclic vinylogous amides such as **10** would proceed effectively (Scheme 3) to give the key aza-tricycle **11** that would subsequently serve as a common intermediate en route to the five azaphenalene alkaloids

(Fig. 1).¹⁹ On the other hand, *intermolecular* annulations of *exo*-cyclic vinylogous amides **12** (or vinylogous urethanes **13**) with vinyl iminium ion **14** did not give any desired quinolizidine nucleus **15**, thereby thwarting our efforts in the synthesis of members of the quinolizidine and indolizidine families of alkaloids.²⁰ Instead, we identified another product, and we report here our findings in the synthesis of tetrahydroindolizidines accompanied with an unexpected formation of hexahydroquinolines via a carbo-[3+3] annulation.



Scheme 3. An aza-[3+3] pathway to azaphenalenes and quinolizidines.

2. Results and discussions

2.1. An unexpected formation of hexahydroquinolines

Preparations of *exo*-cyclic vinylogous amides **12** and **13** are shown in Scheme 4. The synthesis commenced with either 1,3-pentanedione **16a** or ethyl acetoacetate **16b** and followed Carrié's protocol²¹ that features Weiler's dianion²² addition to 1-bromo-2-chloro-propane, azide substitution, and an intramolecular aza-Wittig of azides **18a** or **18b**. The Z-geometry in **12** and **13** was confirmed via NOE experiments.²¹

Unsuspectingly, with *exo*-cyclic vinylogous amides **12** and **13** in hand, we attempted their aza-[3+3] annulation reactions using vinyl iminium salts **20a–c** generated from their corresponding enals **19a–c** under standard conditions^{5,11–15} (Scheme 5). To our surprise, no desired aza-[3+3] annulation





Figure 1. Alkaloids synthesized via intramolecular aza-[3+3].

Scheme 4. Syntheses of *exo*-cyclic vinylogous amide and urethane.


products **15** were formed, and instead, we isolated hexahydroquinolines **21a–c** and **22b,c** in good yields.

We also employed chiral enal **23** in an attempt to detect possible diastereoselectivity. However, while the reaction of chiral enal **23** with **12** led to the isomeric hexahydroquinolines **24** and **25** in good yield, the selectivity was found to be low, and consequently, the relative stereochemistry was not assigned. It is also noteworthy that using more polar solvents such as DMF or EtOH, we still obtained hexahydroquinoline **22** in good yields.

2.2. A carbo-[3+3] annulation pathway


A plausible mechanism for the formation of these unexpected hexahydroquinolines is initiated through a C-1,4-addition of the vinylogous amide in a Michael fashion to the iminium salt to give intermediate **B** (Scheme 6). Tautomerization of **B** could lead to intermediates **C** and **D** with the latter

one being de-conjugated, and an ensuing C-1,2-addition to the iminium salt in a Mannich manner would give **E**. A sequence of elimination of the secondary amine in **E** and tautomerization would then afford the observed hexahydroquinolines.



Scheme 6. A proposed pathway for the hexahydroquinoline formation.

What we have encountered here for the very first time in our own work with aza-[3+3] annulations is the competing carbo-[3+3] annulation pathway.^{23,24} This finding invokes some unique historical perspectives as shown in Figure 2. Prelog²⁵ in 1949 found that instead of the expected Robinson annulation pathway, a carbo-[3+3] cyclization had occurred to give the bicyclo[5.3.1]undecanone. In 1950, and more relevant to the current study, Stork²⁶ reported the addition of the Stork enamine to acrolein, leading to bicyclo[3.3.1]octanone via a carbo-[3+3] cyclization. These reactions all share a similar pathway: 1,4-addition followed by 1,2-addition.



Scheme 5. Unexpected formation of hexahydroquinolines.





Figure 2. Aza-[3+3] versus carbo-[3+3] annulation.

Despite the fact that this can be a very useful reaction for constructing highly substituted cyclohexane derivatives to compliment the Diels–Alder strategy, much of the earlier work focused on the synthesis of bridged bicyclic systems with an interest in accessing anti-Bredt's olefins.^{23,27} While there has been a surging interest (especially in the synthesis of garsubellin A) given the array of elegant accounts that appeared recently,²⁸ most efforts are still exerted on the synthesis of bridged bicyclic systems.

2.3. Syntheses of quinolines

One immediate application of this carbo-[3+3] annulation is in the synthesis of quinolines, which would also be in accord with the theme of this *Symposium-in-Print*. As shown in Scheme 7, treatment of hexahydroquinolines **21b** and **22b** with 3.0 equiv of DDQ at rt led to quinoline **26** and **27** in 50% and 83% yields, respectively. With less DDQ used, we were able to isolate the respective tetrahydroquinolines **28** and **29**, although there was no apparent selectivity over the extent of aromatization.



Scheme 7. DDQ aromatization in the quinoline synthesis.

2.4. A contrasting reaction pathway

When we directed our attention to pyrrolidine-based *exo*-cyclic vinylogous urethane **30**^{21,29} and vinylogous amide **31**,^{21,30} we were fully intending on preparing a series of tetrahydroindoles via the same carbo-[3+3] annulation (Fig. 3). We were not prepared for additional surprises.




Figure 3. A possible synthesis of tetrahydroindoles.

However, as shown in Table 1, reactions of **30** and **31** with achiral enals **19a–c** (entries 1–4), or chiral enals **23** and **33–35** (entries 5–9), led to the respective aza-[3+3] annulation products: tetrahydroindolizidines **36–40**. Even when we employed azepane-based *exo*-cyclic vinylogous urethane **32**,^{21,31} we obtained the aza-annulation products **41** and **42** in good yields (entries 10 and 11).

2.5. C-1,2 versus C-1,4-addition

These two contrasting reaction pathways intrigued us. Although we do not have any definitive understanding at this point, one possible cause for is that they mechanistically differ in the very initial step. As shown in Scheme 8, for the pyrrolidine-based *exo*-cyclic vinylogous amide (left), there appears to be a preference for C-1,2-addition, whereas for piperidine-based *exo*-cyclic vinylogous amide (right), the preference is C-1,4-addition.

Specifically, for the pyrrolidine-based vinylogous amide **G-1**, it may react through conformer **G-2** because the internal hydrogen-bonding in **G-1** is not as perfectly aligned or tight as in piperidine-based *exo*-cyclic vinylogous amide **J-1**. Thus, the conformational equilibrium does not shift away from **G-2** or at least not completely, thereby freeing the carbonyl group to participate in hydrogen-bonding with protons of the vinyl iminium salt (in green). This external hydrogen-bonding interaction can in fact provide a stabilization of ~ 14.7 Kcal mol⁻¹.³

With this hydrogen-bonding network in place, C-1,2-addition (red arrow) would be better aligned stereoelectronically than C-1,4-addition (dotted blue arrow), thereby leading to 1-azatriene **H** after β -elimination and subsequently completing the aza-annulation pathway via a pericyclic ring-closure. It is noteworthy that the theoretical observation of this external hydrogen-bonding network likely provides a major rationale for

Table 1
Aza-[3+3] annulations of *exo*-cyclic vinylogous amides

Entry	Amides	Aldehydes	Aza-[3+3] products	Yield (%) ^a	Ratio ^b
1	30 ^c	19a : R ¹ = Me	36a : R = OMe; R ¹ = Me	51	—
2	30	19b : R ¹ = <i>n</i> -Pr	36b : R = OMe; R ¹ = <i>n</i> -Pr	70	—
3	30	19c : R ¹ = Ph	36c : R = OMe; R ¹ = Ph	75	—
4	31 ^d	19b : R ¹ = <i>n</i> -Pr	36d : R = Me; R ¹ = <i>n</i> -Pr	73	—
5		23	37	56	1.5:1
6	30	33	38	50	1.3:1
7	30	34	39a : R = OMe	10	≥20:1
8	31	34	39b : R = Me	7	≥20:1
9	30	35	40	33	2.2:1 ^e
10	32 ^f	19c	41	53	—
11	32	23	42	62	1.2:1

^a Isolated yields.

^b Ratio determined using ¹H NMR, and unless noted otherwise, the relative stereochemistry was not assigned.

^c See Refs. 21 and 29 for the preparation of **30**.

^d See Refs. 21 and 30 for the preparation of **31**.

^e The ratio was found in crude ¹H NMR but the minor isomer appeared to isomerize to the major isomer during purification. The major isomer shown here was assigned using NOE experiment and the final ratio was 13.8:1.


^f See Refs. 21 and 31 for the preparation of **32**.

the high level of regioselectivity found in most of our annulation work^{5a,32} involving vinyl iminium salts, especially when comparing with protocols in which vinyl iminium salts are generated in situ or not employed.^{33,34}

On the other hand, for piperidine-based *exo*-cyclic vinylogous amide, conformer **J-1** dominates due to the strong internal hydrogen-bonding (in green), which precludes the carbonyl group in **J-1** from participating in the related external hydrogen-bonding network. With both options of C-1,2- and C-1,4-additions being available, C-1,4-addition (solid blue arrow) could take precedent based on the 'hard-and-soft' concept.

This would allow the piperidine-based *exo*-cyclic vinylogous amide (or urethane) to follow the carbo-annulation pathway.

In addition, although all of these mechanistic steps are reversible, our calculations using B3LYP/6-31G* [SpartanTM] suggest (Fig. 4) that the observed dichotomy of these two reaction pathways cannot be attributed as a result of thermodynamic equilibration. For all three cases, pyrrolidine-, piperidine-, and azepane-based vinylogous amides or urethanes, the respective carbo-annulation products are thermodynamically more favored than their corresponding aza-annulation products, although in a relatively lesser extent for both the



Scheme 8. C-1,2 addition versus C-1,4-addition.




Figure 4. Energetic differences in the annulation products.

pyrrolidine-based vinylogous amide and azepane-based vinylogous urethane.

3. Conclusion

We have described here [3+3] annulations of *exo*-cyclic vinylogous amides and urethanes with vinyl iminium salts and observed an intriguing dichotomy in their reaction pathways. For pyrrolidine- and azepane-based vinylogous amide or urethanes, aza-[3+3] annulation dominates to give tetrahydroindolizidines, whereas the piperidine-based vinylogous amide or urethane underwent an unexpected carbo-[3+3] annulation to afford hexahydroquinolines. The origin for such a contrast is not clear at this moment, although we suspect it is associated with an initial preference for either C-1,2-addition or C-1,4-addition. This work provides a useful approach toward either total syntheses of the indolizidine family of natural products or functionalized quinolines.

4. Experimental section

4.1. General

All reactions were performed in flame-dried glassware under a nitrogen atmosphere. Solvents were distilled prior to use. Reagents were used as purchased (Aldrich, Acros), except where noted. Chromatographic separations were performed using Bodman 60 Å SiO₂. ¹H and ¹³C NMR spectra were obtained on Varian VI-300, VI-400, and VI-500 spectrometers using CDCl₃ (except where noted) with TMS or residual CHCl₃ in the solvent as standard. Melting points were determined using a Laboratory Devices MEL-TEMP and are uncorrected/calibrated. Infrared spectra were obtained using NaCl plates on a Bruker Equinox 55/S FTIR Spectrophotometer, and relative intensities are expressed qualitatively as s (strong), m (medium), and w (weak). TLC analysis was performed using Aldrich 254 nm polyester-backed plates (60 Å, 250 μm) and visualized using UV and a suitable chemical stain.

Low-resolution mass spectra were obtained using an Agilent-1100-HPLC/MSD and can be either APCI or ESI, or an IonSpec HiRes-MALDI FT-Mass Spectrometer. High-resolution mass spectral analyses were performed at University of Wisconsin Mass Spectrometry Laboratories. All spectral data obtained for new compounds are reported.

4.2. General procedure for all annulations

To a solution of an enal (1.40 mmol, 1.40 equiv) in EtOAc/toluene (3.5 to 5 mL with a ratio of 2:3) in a sealed tube were added Na₂SO₄ (400.0 mg), piperidinium acetate (1.40 mmol, 1.40 equiv), and the respective vinylogous amide (1.00 mmol) sequentially. After stirring at rt for 1 min, the

mixture was heated at 95–100 °C for 3–4 h. The reaction progress was monitored using TLC analysis and/or crude ^1H NMR. When the starting material completely disappeared, the reaction mixture was cooled and the excess amine salt was filtered off through a small cotton plug (or CeliteTM), and the excess solvent was evaporated under reduced pressure. The crude residue was purified by flash silica gel column chromatography (gradient eluent: EtOAc in hexanes) to provide the corresponding annulation product.

4.2.1. Carbo-[3+3] annulation product **21a**

$R_f=0.10$ (30% EtOAc/hexane); ^1H NMR (400 MHz, CDCl_3) δ 0.96 (d, 3H, $J=6.8$ Hz), 1.66–1.75 (m, 1H), 1.84 (ddd, 1H, $J=4.3, 8.8, 21.8$ Hz), 1.94 (s, 1H), 2.05 (dd, 1H, $J=6.5, 17.4$ Hz), 2.10 (s, 3H), 2.29–2.48 (m, 2H), 2.72 (p, 1H, $J=7.0$ Hz), 3.32 (ddd, 2H, $J=2.7, 3.8, 6.8$ Hz), 5.87 (d, 1H, $J=6.5$ Hz), 11.86 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 20.6, 22.7, 26.6, 27.7, 28.5, 31.9, 41.5, 102.7, 128.5, 131.9, 154.0, 193.6; IR (neat) cm^{-1} 2951brm, 2860brm, 1569s, 1550s, 1480m, 1450m, 1364m, 1348m, 1252s; mass spectrum (APCI): m/e (% relative intensity) 192 (100) ($\text{M}+\text{H}$)⁺, 150 (5), 140 (10); m/e (ESI) calcd for $\text{C}_{12}\text{H}_{17}\text{NO}$ 191.1310, found 191.1309.

4.2.2. Carbo-[3+3] annulation product **21b**

$R_f=0.26$ (30% EtOAc/hexanes); ^1H NMR (500 MHz, CDCl_3) δ 0.89 (t, 3H, $J=7.2$ Hz), 1.13–1.20 (m, 2H), 1.28–1.32 (m, 1H), 1.38–1.45 (m, 1H), 1.67–1.74 (m, 1H), 1.80–1.85 (m, 1H), 2.09 (s, 3H), 2.19–2.41 (m, 4H), 2.50–2.54 (m, 1H), 3.32 (dd, 2H, $J=4.0, 7.0$ Hz), 5.85 (d, 1H, $J=6.0$ Hz), 11.90 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.4, 21.0, 22.8, 26.7, 28.4, 28.6, 32.7, 36.6, 41.6, 102.7, 129.0, 132.2, 154.4, 193.6; IR (neat) cm^{-1} 2955brm, 2869brm, 1569s, 1543s, 1257s; mass spectrum (APCI): m/e (% relative intensity) 220 (100) ($\text{M}+\text{H}$)⁺; m/e (ESI) calcd for $\text{C}_{14}\text{H}_{22}\text{NO}$ 220.1701, found 220.1703.

4.2.3. Carbo-[3+3] annulation product **21c**

$R_f=0.36$ (50% EtOAc/hexanes); ^1H NMR (500 MHz, CDCl_3) δ 1.82–1.84 (m, 1H), 1.88–1.98 (m, 1H), 1.97 (s, 3H), 2.41–2.53 (m, 3H), 2.84–2.91 (m, 1H), 3.48–3.50 (m, 2H), 3.99 (d, 1H, $J=8.0$ Hz), 5.80 (d, 1H, $J=5.5$ Hz), 7.19–7.31 (m, 5H), 12.06 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 22.9, 27.2, 28.5, 33.4, 38.5, 41.8, 99.1, 126.3, 127.8, 128.3, 128.4, 129.8, 131.1, 145.7, 155.4; IR (neat) cm^{-1} 2940brm, 2859brm, 1670s, 1577s, 1552, 1273s; mass spectrum (APCI): m/e (% relative intensity) 254 (100) ($\text{M}+\text{H}$)⁺; m/e (ESI) calcd for $\text{C}_{17}\text{H}_{20}\text{NO}$ 254.1545, found 254.1534.

4.2.4. Carbo-[3+3] annulation product **22b**

$R_f=0.29$ (10% EtOAc/hexanes); ^1H NMR (500 MHz, CDCl_3) δ 0.87 (t, 3H, $J=7.0$ Hz), 1.16–1.35 (m, 7H), 1.68–1.76 (m, 1H), 1.81–1.87 (m, 1H), 2.16 (dd, 1H, $J=6.0, 16.5$ Hz), 2.29–2.42 (m, 3H), 2.72 (q, 1H, $J=5.0$ Hz), 3.29–3.34 (m, 2H), 4.06–4.15 (m, 2H), 5.81 (d, 1H, $J=6.0$ Hz), 9.17 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.4, 14.8, 20.7, 23.3, 28.3, 29.0, 29.9, 36.3, 41.8, 58.6, 90.7, 128.9,

130.5, 152.6, 170.9; IR (neat) cm^{-1} 2956brm, 2864brm, 1630s, 1578s, 1243s; mass spectrum (APCI): m/e (% relative intensity) 250 (100) ($\text{M}+\text{H}$)⁺; m/e (ESI) calcd for $\text{C}_{15}\text{H}_{24}\text{NO}_2$ 250.1807, found 250.1807.

4.2.5. Carbo-[3+3] annulation product **22c**

$R_f=0.28$ (10% EtOAc/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 1.12 (t, 3H, $J=7.0$ Hz), 1.77–1.93 (m, 2H), 2.39–2.45 (m, 3H), 2.76–2.83 (m, 1H), 3.40–3.44 (m, 2H), 3.95–4.12 (m, 3H), 5.77 (d, 1H, $J=5.6$ Hz), 7.14–7.24 (m, 5H), 9.42 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.8, 23.3, 29.0, 32.4, 36.2, 41.9, 58.8, 88.1, 125.9, 127.6, 128.0, 129.8, 130.0, 146.9, 153.8, 170.9; IR (neat) cm^{-1} 2945brm, 2860brm, 1630s, 1584s, 1273s; mass spectrum (APCI): m/e (% relative intensity) 284 (100) ($\text{M}+\text{H}$)⁺; m/e (ESI) calcd for $\text{C}_{18}\text{H}_{22}\text{NO}_2$ 284.1654, found 284.1642.

4.2.6. Chiral carbo-[3+3] annulation products **24** and **25** (characterized as an inseparable mixture)

$R_f=0.16$ (50% EtOAc/hexane); ^1H NMR (500 MHz, CDCl_3) δ major diastereomer: 1.30 (s, 3H), 1.39 (s, 3H), 1.69–1.90 (m, 2H), 2.13–2.18 (m, 1H), 2.23 (s, 3H), 2.33–2.45 (m, 3H), 2.86 (t, 1H, $J=7.5$ Hz), 3.30–3.37 (m, 2H), 3.59 (t, 1H, $J=7.5$ Hz), 3.91–3.97 (m, 1H), 4.06–4.11 (m, 1H), 5.91 (d, 1H, $J=6.0$ Hz), 12.1 (s, 1H, NH); minor diastereomer (partial listing due to unresolved overlapping resonances): 1.31 (s, 3H), 1.69–1.90 (m, 3H), 2.20 (s, 3H), 2.33–2.45 (m, 3H), 2.53–2.58 (m, 1H), 2.77 (t, 1H, $J=7.5$ Hz), 3.30–3.37 (m, 2H), 3.65 (dd, 1H, $J=5.5, 8.5$ Hz), 3.82 (dd, 1H, $J=5.5, 8.5$ Hz), 3.95–3.97 (m, 1H), 5.97 (d, 1H, $J=5.5$ Hz); IR (film): cm^{-1} 2934brw, 1662w, 1609m, 1571s, 1554s; mass spectrum (APCI): m/e (% relative intensity) 278 (100) ($\text{M}+\text{H}$)⁺, 236 (10), 140 (20), 101 (10); m/e (ESI) calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_3$ 278.1756, found 278.1762.

4.3. General procedure for the DDQ aromatization

To a solution of **21b** (30.0 mg, 0.136 mmol) in CH_2Cl_2 (3 mL) was added DDQ (93.0 mg, 0.40 mmol, 3.00 equiv). The reaction mixture was stirred at rt for 1 h and the reaction progress was monitored using TLC analysis. When the starting material completely disappeared, the reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash silica gel column chromatography (gradient eluent: 0–25% EtOAc in hexanes) to provide the desired quinoline **26** (14.5 mg, 50%).

4.3.1. Quinoline **26**

$R_f=0.39$ (20% EtOAc/hexanes); ^1H NMR (500 MHz, CDCl_3) δ 0.98 (t, 3H, $J=7.5$ Hz), 1.69–1.74 (m, 2H), 2.68–2.71 (m, 2H), 2.72 (s, 3H), 7.37 (dd, 1H, $J=4.5, 8.5$ Hz), 7.41 (d, 1H, $J=8.5$ Hz), 7.75 (d, 1H, $J=8.5$ Hz), 8.11 (dd, 1H, $J=2.0, 8.5$ Hz), 8.86 (dd, 1H, $J=1.5, 4.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 14.4, 25.0, 33.9, 35.7, 121.0, 126.5, 128.2, 128.8, 135.8, 139.5, 140.3, 145.8, 150.4, 207.8; IR (neat) cm^{-1} 2961m, 2871m, 1705s, 1572m; mass spectrum

(APCI): *m/e* (% relative intensity) 214 (100) (M+H)⁺; *m/e* (ESI) calcd for C₁₄H₁₅NONa 236.1051, found 236.1053.

4.3.2. Quinoline 27

R_f=0.11 (10% EtOAc/hexane); ¹H NMR (400 MHz, CDCl₃) δ 1.01 (t, 3H, *J*=7.2 Hz), 1.46 (t, 3H, *J*=7.2 Hz), 1.72–1.81 (m, 2H), 2.78 (dt, 2H, *J*=6.0, 7.6 Hz), 4.59 (q, 2H, *J*=7.2 Hz), 7.38 (dd, 1H, *J*=4.0, 8.0 Hz), 7.40 (d, 1H, *J*=8.8 Hz), 7.79 (d, 1H, *J*=8.4 Hz), 8.11 (dd, 1H, *J*=2.0, 8.4 Hz), 8.93 (dd, 1H, *J*=2.0, 4.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 14.3, 14.6, 24.6, 36.3, 61.6, 121.1, 126.5, 128.3, 128.7, 133.1, 135.8, 140.9, 145.7, 151.1, 169.7; IR (film) cm⁻¹: 2962brw, 2872w, 1725s, 1613w, 1569w, 1499w, 1459brw, 1370w, 1265s; mass spectrum (APCI): *m/e* (% relative intensity) 244 (100) (M+H)⁺, 198 (20), 101 (5); *m/e* (ESI) calcd for C₁₅H₁₈NO₂ 244.1338, found 244.1349.

4.3.3. Tetrahydroquinoline 28

R_f=0.50 (20% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, 3H, *J*=7.2 Hz), 1.55–1.61 (m, 2H), 1.84–1.90 (m, 2H), 2.48 (s, 3H), 2.52–2.56 (m, 2H), 2.72 (t, 2H, *J*=5.6 Hz), 3.27 (t, 2H, *J*=3.6 Hz), 5.30 (br s, 1H), 6.43 (d, 1H, *J*=7.6 Hz), 6.88 (d, 1H, *J*=3.6 Hz); mass spectrum (APCI): *m/e* (% relative intensity) 218 (100) (M+H)⁺; *m/e* (ESI) calcd for C₁₄H₂₀NO 218.1545, found 218.1554.

4.3.4. Tetrahydroquinoline 29

R_f=0.29 (10% EtOAc/hexanes); ¹H NMR (500 MHz, CDCl₃) δ 0.94 (t, 3H, *J*=7.5 Hz), 1.39 (t, 3H, *J*=7.0 Hz), 1.55–1.61 (m, 2H), 1.88 (dt, 2H, *J*=5.0, 6.5 Hz), 2.68 (m, 2H), 2.74 (t, 2H, *J*=6.0 Hz), 3.35 (t, 2H, *J*=6.0 Hz), 4.35 (q, 2H, *J*=7.0 Hz), 6.38 (d, 1H, *J*=7.5 Hz), 6.89 (d, 1H, *J*=7.5 Hz); IR (film) cm⁻¹: 2957m, 2929m, 1725w, 1679m, 1599w, 1582w, 1507m; mass spectrum (APCI): *m/e* (% relative intensity) 248.2 (100) (M+H)⁺, 202 (65), 101 (5); *m/e* (ESI) calcd for C₁₅H₂₂NO₂ 248.1651, found 248.1658.

4.4. General procedure

See Section 4.2.

4.4.1. Aza-[3+3] annulation product 36a

R_f=0.27 (20% EtOAc/hexane); ¹H NMR (400 MHz, CDCl₃) δ 0.99 (d, 3H, *J*=6.4 Hz), 1.88–2.00 (m, 2H), 2.92 (dt, 1H, *J*=9.1, 18.1 Hz), 3.10 (ddd, 1H, *J*=4.5, 8.6, 18.1 Hz), 3.29 (q, 1H, *J*=9.1 Hz), 3.36 (p, 1H, *J*=6.4 Hz), 3.52 (ddd, 1H, *J*=4.1, 8.0, 9.1 Hz), 3.65 (s, 3H), 4.88 (dd, 1H, *J*=5.5, 7.6 Hz), 5.92 (d, 1H, *J*=7.6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 21.8, 25.0, 28.5, 32.0, 50.5, 51.1, 95.4, 110.6, 125.2, 155.1, 169.2; IR (neat) cm⁻¹: 2947brm, 2862brm, 1672s, 1578s, 1256s, 1219s, 1094s; mass spectrum (APCI): *m/e* (% relative intensity) 194 (100) (M+H)⁺, 162 (15); *m/e* (ESI) calcd for C₁₁H₁₆NO₂ 194.1181, found 194.1188.

4.4.2. Aza-[3+3] annulation product 36b

R_f=0.22 (10% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 8.25 (t, 3H, *J*=7.2 Hz), 1.17–1.32 (m, 4H), 1.83–

1.94 (m, 2H), 2.87 (ddd, 1H, *J*=9.2, 18.0, 36.0 Hz), 3.25 (ddd, 1H, *J*=4.4, 8.8, 18.0 Hz), 3.25 (q, 1H, *J*=7.2 Hz), 3.30–3.34 (m, 1H), 3.49 (ddd, 1H, *J*=4.0, 8.4, 12.0 Hz), 3.61 (s, 3H), 4.87 (dd, 1H, *J*=5.6, 7.6 Hz), 5.95 (d, 1H, *J*=7.6 Hz); ¹³C NMR (125 MHz, CDCl₃) δ 14.5, 18.1, 22.0, 32.0, 33.2, 41.2, 50.5, 51.2, 94.2, 108.9, 126.0, 155.6, 169.4; IR (neat) cm⁻¹: 2951brm, 2869brm, 1673s, 1578s, 1194s; mass spectrum (APCI): *m/e* (% relative intensity) 222 (100) (M+H)⁺; *m/e* (ESI) calcd for C₁₃H₂₀NO₂ 222.1494, found 222.1504.

4.4.3. Aza-[3+3] annulation product 36c

R_f=0.35 (20% EtOAc/hexanes); ¹H NMR (500 MHz, CDCl₃) δ 2.02–2.11 (m, 2H), 3.10 (dt, 1H, *J*=9.0, 18.0 Hz), 3.28 (ddd, 1H, *J*=5.0, 9.0, 18 Hz), 3.45 (q, 1H, *J*=8.0 Hz), 3.62 (s, 3H), 3.65 (ddd, 1H, *J*=4.5, 9.0, 9.0 Hz), 4.64 (d, 1H, *J*=5.5 Hz), 5.08 (dd, 1H, *J*=5.0, 7.5 Hz), 6.12 (d, 1H, *J*=5.5 Hz), 7.20–7.23 (m, 1H), 7.29–7.35 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 21.9, 32.2, 40.2, 50.7, 51.4, 94.6, 109.6, 125.1, 126.3, 127.7, 128.5, 148.9, 154.9, 169.1; IR (neat) cm⁻¹: 2940brm, 2852brm, 1676s, 1595s, 1273s, 1106s; mass spectrum (APCI): *m/e* (% relative intensity) 256 (100) (M+H)⁺, 178 (25); *m/e* (ESI) calcd for C₁₆H₁₇NO₂Na 278.1157, found 278.1165.

4.4.4. Aza-[3+3] annulation product 36d

R_f=0.33 (20% EtOAc/hexane); ¹H NMR (400 MHz, CDCl₃) δ 0.88 (t, 3H, *J*=7.2 Hz), 1.19–1.41 (m, 4H), 1.92–2.07 (m, 2H), 2.19 (s, 3H), 2.95 (dt, 1H, *J*=8.8, 18.0 Hz), 3.19 (ddd, 1H, *J*=4.0, 8.0, 18.0 Hz), 3.33 (dt, 1H, *J*=8.0, 8.8 Hz), 3.37–3.42 (m, 1H), 3.59 (ddd, 1H, *J*=4.0, 8.0, 9.6 Hz), 5.06 (dd, 1H, *J*=6.0, 8.0 Hz), 6.03 (d, 1H, *J*=8.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 14.4, 18.1, 21.9, 28.5, 32.9, 33.9, 41.7, 51.1, 105.4, 110.0, 125.9, 155.3, 196.6; IR (film) cm⁻¹: 2953m, 2869m, 2360w, 1659m, 1613m, 1530s, 1395m; mass spectrum (APCI): *m/e* (% relative intensity) 206 (100) (M+H)⁺; *m/e* (EI) calcd for C₁₃H₂₀NO 206.1545, found 206.1549.

4.4.5. Aza-[3+3] annulation product 37 (characterized as a mixture)

R_f=0.42 (50% EtOAc/hexane); ¹H NMR (500 MHz, CDCl₃) δ *major diastereomer*: 1.33 (s, 3H), 1.41 (s, 3H), 1.88–2.05 (m, 2H), 2.95 (dt, 1H, *J*=9.0 Hz), 3.14 (ddd, 1H, *J*=3.5, 8.5, 18.0 Hz), 3.33–3.36 (m, 1H), 3.57 (dt, 1H, *J*=3.5, 8.5 Hz), 3.68 (s, 3H), 3.82 (dd, 1H, *J*=6.5, 8.0 Hz), 3.86–3.90 (m, 2H), 4.18 (dt, 1H, *J*=2.5, 4.5 Hz), 4.96 (dd, 1H, *J*=2.0, 5.5 Hz), 6.19 (d, 1H, *J*=8.0 Hz); *minor diastereomer* (partial listing due to unresolved overlapping resonances): 1.40 (s, 3H), 1.88–2.05 (m, 2H), 2.91–2.98 (m, 1H), 3.15–3.23 (m, 1H), 3.31–3.38 (m, 1H), 3.60–3.65 (m, 2H), 3.95–4.00 (m, 2H), 4.12–4.14 (m, 1H), 5.01 (dd, 1H, *J*=6.0, 7.5 Hz), 6.14 (d, 1H, *J*=7.0 Hz). ¹³C NMR (125 MHz, CDCl₃) δ *from a small sample of resolved major isomer*: 21.8, 25.3, 26.4, 32.2, 36.6, 50.8, 51.2, 66.1, 78.8, 90.1, 94.9, 104.5, 108.8, 128.1, 157.1; IR (film) cm⁻¹: 2984m, 2949w, 1671brs, 1578s, 1414s, 1370s, 1251s; mass spectrum

(APCI): *m/e* (% relative intensity) 280 (30) (M+H)⁺, 248 (100), 222 (90), 178 (25); *m/e* (ESI) calcd for C₁₅H₂₁NO₄Na 302.1368, found 302.1375.

4.4.6. Aza-[3+3] annulation product **38** (characterized as a mixture)

R_f=0.19 (50% EtOAc/hexane); ¹H NMR (500 MHz, CDCl₃) δ *major diastereomer* (partial listing due to unresolved overlapping resonances): 2.83–2.89 (m, 1H), 2.99–3.03 (m, 1H), 3.09–3.15 (m, 1H), 3.66 (s, 3H), 3.83–3.88 (m, 1H), 4.10–4.20 (m, 2H), 4.35 (dd, 1H, *J*=2.0, 12.5 Hz), 4.84 (dd, 1H, *J*=5.5, 7.5 Hz), 5.06 (dd, 1H, *J*=4.0, 7.0 Hz), 5.27–5.32 (m, 1H), 6.18 (d, 1H, *J*=7.5 Hz); *minor diastereomer*: 1.95–1.97 (m, 1H), 2.00 (s, 3H), 2.03 (s, 3H), 2.05 (s, 3H), 2.08–2.1 (m, 1H), 2.94 (dt, 1H, *J*=9.0, 18 Hz), 3.09–3.15 (m, 1H), 3.37 (dd, 1H, *J*=8.0, 17.0 Hz), 3.63–3.66 (m, 1H), 3.69 (s, 3H), 3.85–3.87 (m, 1H), 4.10–4.16 (m, 1H), 4.47 (dd, 1H, *J*=2.5, 12.0 Hz), 4.93 (dd, 1H, *J*=6.0, 7.5 Hz), 4.98 (dd, 1H, *J*=5.0, 7.0 Hz), 5.33 (ddd, 1H, *J*=2.5, 5.0, 7.5 Hz), 6.21 (d, 1H, *J*=7.5 Hz); IR (film) cm^{−1} 2950brw, 1742s, 1676m, 1579m, 1435m, 1371m, 1264s; mass spectrum (APCI): *m/e* (% relative intensity) 396 (100) (M+H)⁺, 336 (20), 194 (5), 101 (10); *m/e* (ESI) calcd for C₁₉H₂₅NO₈Na 418.1478, found 418.1480.

4.4.7. Aza-[3+3] annulation product **39a**

R_f=0.45 (20% EtOAc/hexane); [α]_D²⁵ −303.0 (*c* 0.55, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ *major diastereomer*: 1.55–1.69 (m, 1H), 1.72–1.77 (m, 1H), 1.82 (s, 3H), 1.85–1.87 (m, 1H), 1.91 (dddd, 2H, *J*=8.0 Hz), 2.08–2.21 (m, 2H), 2.28–2.33 (dq, 1H, *J*=2.8, 13.2 Hz), 2.43 (s, 1H), 2.88 (dt, 1H, *J*=8.0, 17.6 Hz), 3.08 (dt, 1H, *J*=7.2, 18.0 Hz), 3.24 (q, 1H, *J*=8.0 Hz), 3.41 (dt, 1H, *J*=6.8, 9.2 Hz), 3.55 (dd, 1H, *J*=3.2, 12.0 Hz), 3.65 (s, 3H), 5.01 (d, 2H, *J*=6.8 Hz), 5.65 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 22.8, 28.6, 31.4, 32.1, 33.8, 39.0, 40.5, 50.3, 50.9, 91.7, 111.3, 117.0, 125.3, 146.8, 155.3, 169.5; IR (film) cm^{−1} 2361w, 1709s, 1580w, 1422w, 1360m; mass spectrum (APCI): *m/e* (% relative intensity) 274 (100) (M+H)⁺; *m/e* (EI) calcd for C₁₇H₂₃NO₂ 273.1729, found 273.1728.

4.4.8. Aza-[3+3] annulation product **39b**

R_f=0.30 (30% EtOAc/hexane); [α]_D²⁵ −449.0 (*c* 0.080, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ *major diastereomer*: 1.59–1.76 (m, 2H), 1.84 (s, 3H), 1.92–2.02 (m, 3H), 2.11–2.29 (m, 6H), 2.43 (s, 1H), 2.89 (dt, 1H, *J*=8.8, 17.6 Hz), 3.11 (dt, 1H, *J*=6.8, 17.6 Hz), 3.30 (dt, 1H, *J*=8.0, 9.2 Hz), 3.48 (dt, 1H, *J*=6.4, 9.2 Hz), 3.65 (dd, 1H, *J*=3.6, 12.0 Hz), 5.02 (d, 2H, *J*=10.0 Hz), 5.70 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.6, 23.1, 28.9, 29.0, 31.8, 33.1, 34.7, 39.4, 40.6, 50.9, 104.2, 111.4, 116.9, 127.0, 147.1, 154.8, 195.6; IR (film) cm^{−1} 2932w, 2360w, 1688m, 1639w, 1540s, 1437m, 1417m, 1276s, 1225m; mass spectrum (APCI): *m/e* (% relative intensity) 258 (100) (M+H)⁺; *m/e* (EI) calcd for C₁₇H₂₃NO 257.1780, found 257.1774.

4.4.9. Aza-[3+3] annulation product **40**

R_f=0.30 (25% EtOAc/hexanes); [α]_D²⁵ −95.2 (*c* 2.05, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ *major diastereomer*: 0.87 (s, 3H), 1.10 (d, 1H, *J*=9.5 Hz), 1.28 (s, 3H), 1.86 (m, 1H), 2.04 (ddd, 1H, *J*=2.5, 6.0, 13.0 Hz), 2.08 (m, 1H), 2.14 (dddd, 1H, *J*=2.0, 4.0, 6.0, 6.0 Hz), 2.36 (dddd, 1H, *J*=0.5, 2.5, 4.0, 9.5, 13.5 Hz), 2.63 (dd, 1H, *J*=5.5, 5.5 Hz), 2.68 (dddd, 1H, *J*=0.5, 2.0, 6.5, 6.5, 10.0 Hz), 2.90 (ddd, 1H, *J*=9.5, 11.0, 18.5 Hz), 2.98 (ddd, 1H, *J*=7.0, 9.5, 11.0 Hz), 3.27 (ddd, 1H, *J*=2.0, 10.0, 18.5 Hz), 3.52 (ddd, 1H, *J*=1.5, 8.5, 9.5 Hz), 3.68 (s, 3H), 4.18 (ddd, 1H, *J*=2.0, 6.0, 9.0 Hz), 6.13 (d, 1H, *J*=2.0 Hz); *minor diastereomer*: 2.26 (m, 1H), 2.53 (dd, 1H, *J*=5.5, 5.5 Hz), 3.43 (ddd, 1H, *J*=2.0, 8.5, 10.0 Hz), 3.67 (s, 3H), 4.43 (ddd, 1H, *J*=2.5, 8.5, 8.5 Hz), 6.02 (d, 1H, *J*=2.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 21.0, 24.0, 27.2, 32.6, 33.2, 37.5, 39.8, 42.3, 50.6, 50.7, 50.8, 51.8, 95.5, 116.9, 129.6, 163.8, 167.4; IR (neat) cm^{−1} 2979w, 2944w, 1732w, 1683s, 1562s, 1435m, 1273s, 1174s, 1116s, 1071s, 910w; mass spectrum (APCI): *m/e* (% relative intensity) 274 (100) (M+1)⁺, 242 (10); (MALDI) mass spectrum (APCI): *m/e* (% relative intensity) 274 (100) (M+1)⁺, 242 (10); *m/e* (MALDI) calcd for C₁₇H₂₄NO₂ (M+H)⁺ 274.1802, found 274.1800 and [(M+H)⁺−H₂] 272.1626.

4.4.10. Aza-[3+3] annulation product **41**

R_f=0.32 (10% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 1.37 (t, 3H, *J*=7.2 Hz), 1.62–1.88 (m, 6H), 2.92 (dd, 1H, *J*=8.4, 14.4 Hz), 3.41–3.61 (m, 3H), 3.97–4.02 (m, 2H), 4.57 (d, 1H, *J*=6.0 Hz), 4.92 (dd, 1H, *J*=5.6, 7.6 Hz), 5.94 (d, 1H, *J*=7.6 Hz), 7.15–7.18 (m, 1H), 7.24–7.29 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 26.5, 27.9, 28.9, 39.9, 52.7, 59.1, 98.3, 107.0, 125.8, 127.2, 128.0, 129.9, 149.0, 155.0, 168.9; IR (neat) cm^{−1} 2927m, 2853brm, 1676s, 1561s, 1186s; mass spectrum (APCI): *m/e* (% relative intensity) 298 (100) (M+H)⁺; *m/e* (ESI) calcd for C₁₉H₂₄NO₂ 298.1807, found 298.1812.

4.4.11. Aza-[3+3] annulation product **42** (characterized as a mixture)

R_f=0.48 (50% EtOAc/hexane); ¹H NMR (500 MHz, CDCl₃) δ *major diastereomer*: 1.25–1.29 (m, 3H), 1.32 (s, 3H), 1.39 (s, 3H), 1.51–1.78 (m, 6H), 2.73 (dd, 1H, *J*=8.5, 14.5 Hz), 3.39–3.56 (m, 3H), 3.78 (dd, 1H, *J*=6.5, 7.5 Hz), 3.85 (dd, 1H, *J*=5.0, 6.0 Hz), 3.89 (dd, 1H, *J*=6.5, 8.0 Hz), 4.08 (m, 1H), 4.14 (q, 2H, *J*=7.0 Hz), 4.81 (dd, 1H, *J*=6.0, 7.5 Hz), 6.07 (d, 1H, *J*=7.5 Hz); *minor diastereomer* (partial listing due to unresolved overlapping resonances): 1.51–1.78 (m, 6H), 2.70–2.76 (m, 1H), 3.30 (dd, 1H, *J*=6.0, 10.0 Hz), 3.39–3.56 (m, 1H), 3.87–3.90 (m, 1H), 4.92 (t, 1H, *J*=7.0 Hz), 6.05 (d, 1H, *J*=7.5 Hz); ¹³C NMR (125 MHz, CDCl₃) δ *from a small sample of resolved major isomer*: 14.6, 25.5, 26.5, 26.7, 28.2, 28.9, 29.1, 36.5, 52.6, 59.6, 66.1, 79.2, 94.4, 102.0, 108.7, 133.1, 157.1, 169.1; IR (film) cm^{−1}: 2983w, 2931m, 1675s, 1552s, 1188s; mass spectrum (APCI): *m/e* (% relative intensity) 322 (100) (M+H)⁺, 276

(100), 264 (50), 220 (5), 101 (10); *m/e* (ESI) calcd for $C_{18}H_{27}NO_4Na$ 344.1838, found 344.1852.

Acknowledgements

Authors thank the NIH [NS38049], NIH [AI57153-05], and UW-Madison for funding.

References and notes

- For reviews, see: (a) Harrity, J. P. A.; Provoost, O. *Org. Biomol. Chem.* **2005**, *3*, 1349; (b) Hsung, R. P.; Kurdyumov, A. V.; Sydorenko, N. *Eur. J. Org. Chem.* **2005**, 23; (c) Coverdale, H. A.; Hsung, R. P. *ChemTracts* **2003**, *16*, 238.
- For a review on vinylogous amide chemistry, see: Kucklander, U. Enaminones as Synthons. In *The Chemistry of Functional Groups: The Chemistry of Enamines Part I*; Rappoport, Z., Ed.; John Wiley and Sons: New York, NY, 1994; p 523.
- For a theoretical account, see: Wang, Y.; De-Cai Fang, D.-C.; Liu, R.-Z. *Tetrahedron* **2005**, *61*, 5663.
- For recent studies in this area, see: (a) Trost, B. M.; Dong, G. *Org. Lett.* **2007**, *9*, 2357; (b) Schmidt, A.; Gütlein, J.-P.; Mkrrchyan, S.; Görls, H.; Langer, P. *Synlett* **2007**, 1305; (c) Pattenden, L. C.; Wybrow, R. A. J.; Smith, S. A.; Harrity, J. P. A. *Org. Lett.* **2006**, *8*, 3089; (d) Shintani, R.; Hayashi, T. *J. Am. Chem. Soc.* **2006**, *128*, 6330; (e) Halliday, J. I.; Chebib, M.; Turner, P.; McLeod, M. D. *Org. Lett.* **2006**, *8*, 3399; (f) Katsuyama, I.; Funabiki, K.; Matsui, M.; Muramatsu, H.; Shibata, K. *Heterocycles* **2006**, *68*, 2087; (g) Bose, D. S.; Kumar, R. K. *Heterocycles* **2006**, *68*, 549; (h) Goodenough, K. M.; Raubo, P.; Harrity, J. P. A. *Org. Lett.* **2005**, *7*, 2993; (i) Goodenough, K. M.; Moran, W. J.; Raubo, P.; Harrity, J. P. A. *J. Org. Chem.* **2005**, *70*, 207; (j) Agami, C.; Dechoux, L.; Hebbe, S.; Ménard, C. *Tetrahedron* **2004**, *60*, 5433; (k) Ji, S.-J.; Jiang, Z.-Q.; Lu, J.; Loh, T.-P. *Synlett* **2004**, 831; (l) Hedley, S. J.; Moran, W. J.; Price, D. A.; Harrity, J. P. A. *J. Org. Chem.* **2003**, *68*, 4286.
- For our work on intermolecular aza-[3+3] annulation, see: (a) Sydorenko, N.; Hsung, R. P.; Darwish, O. S.; Hahn, J. M.; Liu, J. *J. Org. Chem.* **2004**, *69*, 6732; (b) McLaughlin, M. J.; Hsung, R. P.; Cole, K. C.; Hahn, J. M.; Wang, J. *Org. Lett.* **2002**, *4*, 2017; (c) Hsung, R. P.; Wei, L.-L.; Sklenicka, H. M.; Douglas, C. J.; McLaughlin, M. J.; Mulder, J. A.; Yao, L. *J. Org. Lett.* **1999**, *1*, 509.
- For leading references on electrocyclic ring-closures involving 1-azatrienes, see: (a) Maynard, D. F.; Okamura, W. H. *J. Org. Chem.* **1995**, *60*, 1763; (b) de Lera, A. R.; Reischl, W.; Okamura, W. H. *J. Am. Chem. Soc.* **1989**, *111*, 4051; For an earlier account, see: (c) Oppolzer, V. W. *Angew. Chem.* **1972**, *22*, 1108.
- For some recent studies of the ring-closure of azatrienes, see: (a) Trost, B. M.; Gutierrez, A. C. *Org. Lett.* **2007**, *9*, 1473; (b) Meketa, M. L.; Weinreb, S. M. *Org. Lett.* **2007**, *9*, 853; (c) Meketa, M. L.; Weinreb, S. M. *Org. Lett.* **2006**, *8*, 1443; (d) Alajarin, M.; Ortín, M.-M.; Sánchez-Andrada, P.; Vidal, A.; Bautista, D. *Org. Lett.* **2005**, *7*, 5281.
- For a review on rotational preferences leading to diastereomeric induction during a 6π -electron electrocyclic ring-closure see: Okamura, W. H.; de Lera, A. R. *Comprehensive Organic Synthesis*; Trost, B. M.; Fleming, I., Paquette, L. A., Eds.; Pergamon: New York, NY, 1991; Vol. 5, pp 699–750.
- For some examples of torquoselective processes, see: (a) Harmata, M.; Lee, D. R.; Barnes, C. L. *Org. Lett.* **2005**, *7*, 1881; (b) Harmata, M.; Schreiner, P. R.; Lee, D. R.; Kirchhoefer, P. L. *J. Am. Chem. Soc.* **2004**, *126*, 10954; (c) Murakami, M.; Hasegawa, M.; Igawa, H. *J. Org. Chem.* **2004**, *69*, 587; (d) Murakami, M.; Miyamoto, Y.; Ito, Y. *Angew. Chem., Int. Ed.* **2001**, *40*, 189; (e) Murakami, M.; Miyamoto, Y.; Ito, Y. *J. Am. Chem. Soc.* **2001**, *123*, 6441; (f) Giese, S.; Kastrop, L.; Stiens, D.; West, F. G. *Angew. Chem., Int. Ed.* **2000**, *39*, 1970.
- For elegant accounts on stereoselective ring-closure of 1-azatrienes, see: (a) Tanaka, K.; Katsumura, S. *J. Am. Chem. Soc.* **2002**, *124*, 9660; (b) Tanaka, K.; Mori, H.; Yamamoto, M.; Katsumura, S. *J. Org. Chem.* **2001**, *66*, 3099; (c) Tanaka, K.; Kobayashi, T.; Mori, H.; Katsumura, S. *J. Org. Chem.* **2004**, *69*, 5906.
- Sydorenko, N.; Hsung, R. P.; Vera, E. L. *Org. Lett.* **2006**, *8*, 2611.
- Wei, L.-L.; Hsung, R. P.; Xiong, H.; Mulder, J. A.; Nkansah, N. T. *Org. Lett.* **1999**, *1*, 2145.
- Sklenicka, H. M.; Hsung, R. P.; McLaughlin, M. J.; Wei, L.-L.; Gerasuto, A. I.; Brennessel, W. W. *J. Am. Chem. Soc.* **2002**, *124*, 10435.
- Wei, L.-L.; Sklenicka, H. M.; Gerasuto, A. I.; Hsung, R. P. *Angew. Chem., Int. Ed.* **2001**, *40*, 1516.
- Gerasuto, A. I.; Hsung, R. P.; Sydorenko, N.; Slafer, B. W. *J. Org. Chem.* **2005**, *70*, 4248.
- Luo, S.; Zificsak, C. Z.; Hsung, R. P. *Org. Lett.* **2003**, *5*, 4709.
- Sydorenko, N.; Zificsak, C. A.; Gerasuto, A. I.; Hsung, R. P. *Org. Biomol. Chem.* **2005**, *3*, 2140.
- (a) Swidorski, J. J.; Wang, J.; Hsung, R. P. *Org. Lett.* **2006**, *8*, 777; (b) Wang, J.; Swidorski, J. J.; Sydorenko, N.; Hsung, R. P.; Coverdale, H. A.; Kuyava, J. M.; Liu, J. *Heterocycles* **2006**, *70*, 423.
- (a) Gerasuto, A. I.; Hsung, R. P. *Org. Lett.* **2006**, *8*, 4899; (b) Gerasuto, A. I.; Hsung, R. P. *J. Org. Chem.* **2007**, *72*, 2476.
- For a review, see: Michael, J. P. *Nat. Prod. Rep.* **1999**, *16*, 675.
- Lambert, P. H.; Vaultier, M.; Carrié, R. *J. Org. Chem.* **1985**, *50*, 5352. The Z-geometry in all the *exo*-cyclic vinylogous urethanes or amides we prepared was confirmed through NOE experiments. From B3LYP/6-31G* [Spartan™] calculations: $\Delta E=4.62$ Kcal mol⁻¹ in favor of the Z-isomer for **31**; $\Delta E=5.93$ Kcal mol⁻¹ in favor of the Z-isomer for **13**; $\Delta E=6.68$ Kcal mol⁻¹ in favor of the Z-isomer for **32**.
- Huckin, S. N.; Weiler, L. *J. Am. Chem. Soc.* **1974**, *96*, 1082.
- For reviews, see: (a) Feist, H.; Langer, P. *Synthesis* **2007**, 327; (b) Butkus, E. *Synlett* **2001**, 1827; (c) Filippini, M.-H.; Rodriguez, J. *Chem. Rev.* **1999**, *99*, 27; (d) Filippini, M.-H.; Faure, R.; Rodriguez, J. *J. Org. Chem.* **1995**, *60*, 6872 and see Refs. 21–33 cited therein; (e) Rappoport, Z. *The Chemistry of Enamines*. In *The Chemistry of Functional Groups*; John Wiley and Sons: New York, NY, 1994; (f) Kraus, G. A.; Hon, Y.-S.; Thomas, P. J.; Laramay, S.; Liras, S.; Hanson, J. *Chem. Rev.* **1989**, *89*, 1591; (g) Keese, R. *Angew. Chem., Int. Ed. Engl.* **1975**, *14*, 528.
- For defining the phrase '[3+3] carbo-cyclizations,' see: Seebach, D.; Missbach, M.; Calderari, G.; Eberle, M. *J. Am. Chem. Soc.* **1990**, *112*, 7625.
- Prelog, V. *J. Chem. Soc.* **1950**, 420.
- (a) Stork, G.; Brizzolara, A.; Landesman, H.; Szmuszkovicz, J.; Terrell, R. *J. Am. Chem. Soc.* **1963**, *85*, 207; (b) Stork, G.; Landesman, H. *J. Am. Chem. Soc.* **1956**, *78*, 5129.
- For earlier studies, see: (a) Dauben, W. G.; Bunce, R. A. *J. Org. Chem.* **1983**, *48*, 4642; (b) Liu, H.-J.; Ho, L.-K.; Lai, H. K. *Can. J. Chem.* **1981**, *59*, 1685; (c) Alexakis, A.; Chapdelaine, M. J.; Posner, G. H. *Tetrahedron Lett.* **1978**, *19*, 4209; (d) Hajos, Z. G.; Parrish, D. R. *J. Org. Chem.* **1974**, *39*, 1612; (e) Hendrickson, J. H.; Boeckman, R. K., Jr. *J. Am. Chem. Soc.* **1971**, *93*, 1307; (f) Warnhoff, E. W.; Wong, C. M.; Tai, W.-T. *J. Org. Chem.* **1967**, *32*, 2664; (g) Buchanan, G. L.; Maxwell, C.; Henderson, W. *Tetrahedron* **1965**, *21*, 3273.
- For recent studies, see: (a) Ahmad, N. M.; Rodeschini, V.; Simpkins, N. S.; Ward, S. E.; Blake, A. J. *J. Org. Chem.* **2007**, *72*, 4803; (b) Hussain, I.; Nguyen, V. T. H.; Yawer, M. A.; Dang, T. T.; Fischer, C.; Reinke, H.; Langer, P. *J. Org. Chem.* **2007**, *72*, 6255; (c) Hong, B.-C.; Wu, M. F.; Tseng, H.-C.; Liao, J.-H. *Org. Lett.* **2006**, *8*, 2217; (d) Bose, G.; Nguyen, V. T.; Ullah, E.; Lahiri, S.; Görls, H.; Langer, P. *J. Org. Chem.* **2004**, *69*, 9128; (e) Dede, R.; Langer, P. *Tetrahedron Lett.* **2004**, *45*, 9177; (f) Kraus, G. A.; Nguyen, T. H.; Jeon, I. *Tetrahedron Lett.* **2003**, *44*, 659; (g) Ciochina, R.; Grossman, R. B. *Org. Lett.* **2003**, *5*, 4619; (h) Hong, B.-C.; Gupta, A. K.; Wu, M.-F.; Liao, J.-H.; Lee, G.-H. *Org. Lett.* **2003**, *5*, 1689 and references cited therein; (i) Young, D. G. J.; Zeng, D. *J. Org. Chem.* **2002**, *67*, 3134; (j) Spessard, S. J.; Stoltz, B. M. *Org. Lett.* **2002**, *4*, 1943; (k) Usuda, H.; Kanai, M.; Shibasaki, M. *Org. Lett.* **2002**, *4*, 859; (l) Ishikawa, T.; Kadoya, R.; Arai, M.; Takahashi, H.; Kaisi, Y.; Mizuta, T.; Yoshikai, K.; Saito, S. *J. Org. Chem.* **2001**, *66*, 8000; (m) Filippini, M.-H.; Rodriguez, J.; Santelli, M. *J. Chem. Soc., Chem. Commun.* **1993**, 1647 and 571; (n) Lapiere, J. M.; Gravel, D. *Tetrahedron Lett.* **1991**, *32*, 2319; Also see: (o) Kuramochi, A.; Usuda, H.; Yamatsugu, K.; Kanai, M.; Shibasaki, M. *J. Am. Chem. Soc.* **2005**, *127*, 14200; (p) Siegal, D. R.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2006**, *128*, 1048.

29. For the synthesis of **30**: (a) Shiosaki, K. *The Eschenmoser Coupling Reaction*; Trost, B. M., Fleming, I., Eds.; Comprehensive Organic Synthesis; Pergamon: Oxford, 1991; Vol. 2, p 865; (b) Pinnick, H. W.; Chang, Y.-H. *J. Org. Chem.* **1978**, *43*, 4662.
30. For the synthesis of **31**: Park, K.-H.; Marshall, W. J. *J. Org. Chem.* **2005**, *70*, 2075.
31. For the synthesis of **32**: (a) Benson, R. E.; Cairns, T. L. *Org. Syn. Coll. Vol.* **1989**, *4*, 588; (b) Celerier, J. P.; Deloisy-Marchalant, E.; Lhomme, G.; Maitte, P. *Org. Syn. Coll. Vol.* **1993**, *8*, 263.
32. (a) For our oxa-[3+3] annulation work, see: Shen, H. C.; Wang, J.; Cole, K. P.; McLaughlin, M. J.; Morgan, C. D.; Douglas, C. J.; Hsung, R. P.; Coverdale, H. A.; Gerasyuto, A. I.; Hahn, J. M.; Liu, J.; Wei, L.-L.; Sklenicka, H. M.; Zehnder, L. R.; Zifcick, C. A. *J. Org. Chem.* **2003**, *68*, 1729; (b) Hsung, R. P.; Shen, H. C.; Douglas, C. J.; Morgan, C. D.; Degen, S. J.; Yao, L. J. *J. Org. Chem.* **1999**, *64*, 690.
33. For a notable citation supporting the usage of α,β -unsaturated iminium salts, see: Cravotto, G.; Nano, G. M.; Tagliapietra, S. *Synthesis* **2001**, 49.
34. (a) de March, P.; Moreno-Mañas, M.; Casado, J.; Pleixats, R.; Roca, J. L. *J. Heterocycl. Chem.* **1984**, *21*, 85. Also see: (b) Stevenson, R.; Weber, J. V. *J. Nat. Prod.* **1988**, *51*, 1215; (c) Schuda, P. F.; Price, W. A. *J. Org. Chem.* **1987**, *52*, 1972; (d) Tietze, L. F.; Kiedrowski, G. v.; Berger, B. *Synthesis* **1982**, 683; (e) de Groot, A.; Jansen, B. J. M. *Tetrahedron Lett.* **1975**, *16*, 3407.